Wolters Kluwer Health and Logical Images Partner to Offer VisualDx Diagnosis Support Tool to Lexicomp Customers

Published on:

HUDSON, Ohio--Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that the partnership between its drug information solution, Lexicomp®, and digital medical image library, Logical Images®, is continuing to grow, with Lexicomp now offering subscriptions to Logical Images’ flagship solution VisualDx®. Designed to assist in the diagnosis of diseases that prevent visually, VisualDx can help individual Lexicomp users enhance patient care and promote shared decision making to strengthen the patient-physician relationship.

Now available for individual customers to order on its website, Lexicomp offers a VisualDx package that includes an online subscription and mobile app download. Both platforms provide access to 30,000 easily searchable images that clinicians can compare to their patients’ visible symptoms to assist in the diagnosis and treatment of 1,300 diseases and conditions. Dermatologists, other physicians, advanced practice nurses and physician assistants frequently use VisualDx and its library of images to help patients better understand their conditions. When diagnoses are met with disbelief and denial, patients are often more receptive when a clinician can use visuals to communicate a diagnosis and treatment plan.

“VisualDx is a natural complement to Lexicomp drug information resources, as both place a high value on clear, relevant information clinicians can access and assess efficiently at the point of care,” stated Steven Kerscher, Vice President & General Manager, Clinical Drug Information, Wolters Kluwer Health, Clinical Solutions. “Lexicomp is proud to further support safe diagnoses and superior patient care by offering its clinicians a chance to purchase this unique VisualDx solution.”

About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health’s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medi-Span®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion (US$4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.

Contacts

Wolters Kluwer Health|Clinical Solutions
Meagan McCord, Manager, Marketing Communications, 330-650-6506
meagan.mccord@wolterskluwer.com

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.